Applies to Medicare Advantage plans.
Covered with requirementsQualification pathways
You can qualify through any one of these.
CKD with T2DM - renal and CV risk reduction
All of:
- Documented lifestyle modifications (nutrition therapy, physical activity, diabetes self-management) attempted
- Confirmed T2DM diagnosis by one of: HbA1c ≥ 6.5%, fasting plasma glucose ≥ 126 mg/dL, or 2-hr plasma glucose ≥ 200 mg/dL during OGTT (with dates)
- Chronic kidney disease (CKD) with GFR < 60 mL/min/1.73 m2
- Patient is on maximally tolerated dose of ACE inhibitor or ARB
Documentation to bring
- Documentation that lifestyle modifications (nutrition therapy, physical activity, diabetes self-management) have been attempted
- Lab results confirming T2DM diagnosis: HbA1c ≥ 6.5%, OR fasting plasma glucose ≥ 126 mg/dL, OR 2-hr plasma glucose ≥ 200 mg/dL during OGTT (with dates for all labs)
- Lab result confirming CKD with GFR < 60 mL/min/1.73 m2
- Documentation of current ACE inhibitor or ARB use at maximally tolerated dose
Approval and renewal
- Renewal: Therapy discontinuation should be considered if HbA1c is not at goal after 6 months of appropriate use or if patient has intolerable side effects.
Not covered when
- History of medullary thyroid carcinoma (contraindication)
- Multiple endocrine neoplasia type 2 / MEN2 (contraindication)
- Weight loss/obesity as sole indication (excluded from Medicare Part D coverage)
Policy note: CKD indication for Ozempic is listed within the T2DM PA pathway as an AND/OR qualifying criterion. Policy specifies 'reduction of risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with T2DM.' Requires CKD (GFR < 60 mL/min/1.73 m2) on maximally tolerated dose of ACEi or ARB. This pathway does not explicitly require a metformin trial failure, as it is presented as an AND/OR alternative. No UACR threshold specified in this policy document.
source: Clover Health Medicare Advantage prior authorization policy · View policy document (PDF)